



Time is Running Out: Register for the AMCP Pharmacy Policy Summit Today

On Oct. 27, hundreds of managed care and health policy professionals, including payer executives, patient advocacy organizations, and policymakers, will converge on the Gaylord National Harbor Resort for the inaugural [AMCP Pharmacy Policy Summit](#). The one-day Summit, held ahead of [AMCP Nexus 2025](#) from Oct. 28 – 30, offers attendees an insider's look at pressing policy debates such as pharmacy benefit manager (PBM) reform, legislative changes to the Medicare and Medicaid programs, artificial intelligence governance and implications for pharmacy practice, and potential changes to the 340B drug discount program. Attendees will kick off the day with an opening keynote presentation from Robert Costa, National Correspondent and Chief Washington Analyst with CBS News. Attendees who bundle their AMCP Pharmacy Policy Summit registration with AMCP Nexus 2025 registration will save \$100. Luckily, these policy discussions won't stop with the end of the Summit. Through the end of the week, attendees of the full AMCP Nexus 2025 meeting will attend additional educational sessions on trending legislative and regulatory topics, as well as an Oct. 28 General Session presented by former Speaker of the House of Representatives Paul Ryan (R-WI).


[Register Now](#)

The New and Improved AMCP Advocacy Page is Now Live!

This month, AMCP launched the new and improved amcp.org Advocacy landing page. This central repository for all things AMCP Advocacy directs members and the public towards resources on trending policy issues such as the One Big Beautiful Bill ([H.R. 1](#)), [Pharmacy Benefit Manager \(PBM\) reform](#), and [Inflation Reduction Act implementation](#). The new webpage also features one-pagers, briefs, and calls to action supporting AMCP's legislative priorities: the [Access to PDTs Act](#),

the [Medicaid VBPs for Patients \(MVP\) Act](#), and the [Ensuring Community Access to Pharmacist Services \(ECAPS\) Act](#). To view AMCP's full slate of active advocacy campaigns and to make your voice heard at the federal level, simply click the "[Take Action](#)" button, which appears throughout the improved landing page, and enter your information. For the latest, real-time advocacy updates, visitors and members may subscribe to the monthly [Legislative & Regulatory Briefing newsletter](#) and/or [Breaking News alerts](#).

Visit the AMCP Advocacy Landing Page



Trump Administration Tackles Pharmaceutical Tariffs, Global Supply Chain

Over the past several months, the second Trump administration's "America First" trade policy has fully consumed the conversation around global drug supply chains. Just after midnight on the morning of Aug. 7, President Trump's [sweeping](#)

[“reciprocal” tariffs](#) took effect on dozens of international trading partners, marking another dramatic escalation of the carrot-and-stick trading negotiations taken on by the administration. This includes new tariff rates of 50% for India and 39% for Switzerland, while entities like European Union and United Kingdom, who previously negotiated trade deals, will see tariff rates of 10-15% on most products. During an Aug. 5 interview with CNBC, President Trump expressed a desire to place additional tariffs on pharmaceuticals up to 250%, the highest rate threatened on any product thus far. However, the administration has yet to release further details on the implementation of such tariffs, and many experts believe the official announcement [to still be weeks away](#). The President’s interest in global pharmaceutical prices aligns with the resurgence of the Most-Favored-Nation (MFN) pricing scheme [via executive order](#). The order directs the administration to take several actions to compel drug manufacturers to lower prices based on what they charge in other developed countries, which resulted in letters to 17 manufacturers outlining the steps they should take to make the MFN price available to consumers. And while the White House continues its aggressive posturing on the international stage, other agencies are attempting to shore up domestic pharmaceutical production. Attempts include the establishment of [FDA’s new “PreCheck” program](#)—designed to streamline the development of both domestic manufacturing facilities and new therapies—and [a recent executive order](#) directing the government to fill the nation’s Strategic Active Pharmaceutical Ingredients Reserve.

[Read the Blog](#)

Stay Up to Date on H.R. 1 Implementation with AMCP Resources

For the next decade, the federal government, states, and the private sector will be tasked with implementing and accommodating the many provisions of President Trump’s landmark reconciliation package, H.R. 1. While it may be difficult to wrap one’s head around the tangle of effective dates and statutory requirements of this “One Big Beautiful Bill,” AMCP has published several resources to keep members up to date on impending implementation deadlines, as well as analyses on the intended and unintended consequences of the law. This includes [a timeline](#) of implementation milestones for the law’s major health provisions, a line-by-line summary of the law’s final health care provisions, and a webinar recording outlining the impacts of the bill on managed care. AMCP will continue to develop resources

around issues related to H.R. 1, including potential reform and repeal proposals such as [those introduced](#) by Senator Josh Hawley (R-MO).

[View H.R. 1 Resources](#)

[Visit the Member Center](#) | [Explore Ways to Engage](#)

AMCP | 675 North Washington Street, Suite 220 | Alexandria, VA, 22314

[Manage Preferences](#)